Brief: Bio-Rad Q3 Adjusted EPS USD 2.01 Vs. IBES Estimate USD 1.16
30/10/2024 20:15
Oct 30 (Reuters) - Bio-Rad Q3 EPS USD 23.34. * Q3 gross margin 54.8% * Q3 EBIT margin 9.9% * Q3 net income USD 653.2 million * Q3 sales USD 649.7 million vs. IBES estimate USD 628.2 million
Recent news on Bio-Rad Laboratories
See all newsUS RESEARCH ROUNDUP-Cencora, Dave, Uber
Bio-Rad Laboratories, Inc. reports results for the quarter ended September 30 - Earnings Summary
Bio-Rad's Q3 revenue comes slightly above estimates on Clinical Diagnostics growth
Brief: Bio-Rad Q3 EBIT Margin -7.6%
Bio-Rad Laboratories, Inc. reports results for the quarter ended June 30 - Earnings Summary